Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Bitcoin was edging higher on Wednesday, but other cryptocurrencies were having a tougher time of it ahead of a fresh batch of ...
Hosted on MSN14h
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays BullishShares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket ... its gene-editing treatment for sickle cell disease and beta-thalassemia. Analysts responded positively to the results.
Investment losses are painful at any point, but losing stocks are even harder to stomach when the market is in the midst of a ...
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Investor's Business Daily on MSN23h
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback